drugset / Trial / NCT00003143

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

NCT00003143

Phase 2 Completed 20 enrolled Jonsson Comprehensive Cancer Center
RandomizedParallel-groupOpen-labelSupportive care

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy with or without amifostine in treating patients with recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's disease who are undergoing autologous stem cell transplantation.

Timeline

Start
1997-11
Primary completion
2000-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject amifostine Unknown Intravenous
Background Cisplatin Other / unclassified Intravenous
Background Cytarabine Small molecule Intravenous
Background Dexamethasone Small molecule Oral

Indications